vildagliptin

Vildagliptin
Vildagliptin
Vildagliptin
Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetes.
Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model-assessed beta-cell function in patients with type 2 diabetes.
Efficacy and tolerability of vildagliptin monotherapy in drug-naïve patients with type 2 diabetes ☆
Effects of Vildagliptin on Glucose Control Over 24 Weeks in Patients With Type 2 Diabetes Inadequately Controlled With Metformin
Comparison between vildagliptin and metformin to sustain reductions in HbA(1c) over 1 year in drug-naive patients with Type 2 diabet...
Comparison between vildagliptin and metformin to sustain reductions in HbA1c over 1year in drug‐naïve patients with Type2 diab...
Vildagliptin plus metformin combination therapy provides superior glycaemic control to individual monotherapy in treatment-naive pat...
Twelve-week Monotherapy with the DPP-4 Inhibitor Vildagliptin Improves Glycemic Control in Subjects with Type 2 Diabetes
The dipeptidyl peptidase IV inhibitor vildagliptin suppresses endogenous glucose production and enhances islet function after single...
Improved glycaemic control with dipeptidyl peptidase-4 inhibition in patients with type 2 diabetes: vildagliptin (LAF237) dose respo...